Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.

Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and... To evaluate the short-term safety, tolerability, and systemic exposure of a vaginal microbicide gel containing the nonnucleoside reverse transcriptase inhibitor TMC120. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of acquired immune deficiency syndromes (1999) Pubmed

Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.

Jespers, Vicky A; Van Roey, Jens M; Beets, Greet I; Buvé, Anne M
Journal of acquired immune deficiency syndromes (1999) , Volume 44 (2): -145 – Mar 19, 2007
Download PDF

Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.


Abstract

To evaluate the short-term safety, tolerability, and systemic exposure of a vaginal microbicide gel containing the nonnucleoside reverse transcriptase inhibitor TMC120.

Loading next page...
 
/lp/pubmed/dose-ranging-phase-1-study-of-tmc120-a-promising-vaginal-microbicide-5k86kZh8lF

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1525-4135
DOI
10.1097/QAI.0b013e31802bb35f
pmid
17106275

Abstract

To evaluate the short-term safety, tolerability, and systemic exposure of a vaginal microbicide gel containing the nonnucleoside reverse transcriptase inhibitor TMC120.

Journal

Journal of acquired immune deficiency syndromes (1999) – Pubmed

Published: Mar 19, 2007

There are no references for this article.